Celecoxib
- Generic Name
- Celecoxib
- Brand Names
- Celebrex, Elyxyb, Seglentis
- Drug Type
- Small Molecule
- Chemical Formula
- C17H14F3N3O2S
- CAS Number
- 169590-42-5
- Unique Ingredient Identifier
- JCX84Q7J1L
- Background
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon...
- Indication
Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.
...
- Associated Conditions
- Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain
- Associated Therapies
- -
Celecoxib and Rosiglitazone in Treating Patients Who Are Undergoing Cystoscopic Surveillance for Early-Stage Noninvasive Carcinoma of the Bladder or Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder
- Conditions
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2013-07-15
- Lead Sponsor
- Fox Chase Cancer Center
- Registration Number
- NCT00084578
Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
- Conditions
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2013-07-09
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00084448
- Locations
- 🇺🇸
Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States
Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT00084721
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy
- Conditions
- Interventions
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2013-08-22
- Lead Sponsor
- University of Alabama at Birmingham
- Registration Number
- NCT00084370
- Locations
- 🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
Celecoxib Combined With Fluorouracil and Leucovorin in Treating Patients With Resected Stage III Adenocarcinoma (Cancer) of the Colon
- Conditions
- Locations
- 🇦🇹
Innsbruck Universitaetsklinik, Innsbruck, Austria
🇧🇪Ziekenhuis Netwerk Antwerpen Middelheim, Antwerpen, Belgium
🇧🇪CHU Liege - Domaine Universitaire du Sart Tilman, Liege, Belgium
Vaccine Therapy and Radiation to Liver Metastasis in Patients With CEA-Positive Solid Tumors
- Conditions
- First Posted Date
- 2004-04-22
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT00081848
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Neoadjuvant Celecoxib and Capecitabine Combined With Pelvic Irradiation in Treating Patients With Stage II or Stage III Adenocarcinoma (Cancer) of the Rectum
- Conditions
- Interventions
- First Posted Date
- 2004-04-08
- Last Posted Date
- 2016-12-15
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 3
- Registration Number
- NCT00081224
Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases
- Conditions
- Interventions
- First Posted Date
- 2004-04-08
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 14
- Registration Number
- NCT00080782
- Locations
- 🇺🇸
M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
- Conditions
- Interventions
- First Posted Date
- 2004-04-08
- Last Posted Date
- 2017-09-15
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 130
- Registration Number
- NCT00081263
- Locations
- 🇺🇸
Elkhart Clinic, Elkhart, Indiana, United States
🇺🇸Michiana Hematology Oncology PC-Elkhart, Elkhart, Indiana, United States
🇺🇸Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2004-01-12
- Last Posted Date
- 2020-07-27
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT00075673
- Locations
- 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.